Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | APAF1 | O14727 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10257181 | 0.80 | MMP12 (0.38) | SMN1; SMN2NPC1RAB9AMAPTGAA | |
| SCHEMBL828814 | 0.79 | FAAH (0.39) | LMNAMAPTTSHR | |
| SCHEMBL23589324 | 0.76 | TSHR (0.33) | TSHROPRD1 | |
| SCHEMBL23612453 | 0.76 | PARP1 (0.42) | TSHRL3MBTL1CYP1A2 | |
| SCHEMBL6155424 | 0.75 | CYP4F2 (0.36) | TSHR | |
| SCHEMBL6156513 | 0.75 | ALDH1A1 (0.42) | RAB9AMAPTGAAKDM4EMEN1 | |
| SCHEMBL6157517 | 0.75 | HIF1A (0.35) | TSHR | |
| SCHEMBL960318 | 0.75 | MAPT (0.46) | NPC1RAB9AMAPTKDM4EKMT2A | |
| SCHEMBL28746936 | 0.75 | MAOB (0.33) | TDP1ALDH1A1TSHR | |
| SCHEMBL30044913 | 0.75 | ALDH1A1 (0.42) | RAB9AMAPTGAAKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230123911-A1 | MODULATION OF IMMUNE CELLS | OCTAGON THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2023014360-A1 | TREATMENT AND DIAGNOSIS OF IMMUNE DISORDERS RELATING TO ABERRANT IMMUNE CELLS | OCTAGON THERAPEUTICS, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023014360-A1 | TREATMENT AND DIAGNOSIS OF IMMUNE DISORDERS RELATING TO ABERRANT IMMUNE CELLS | OCTAGON THERAPEUTICS, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-4096673-A1 | MODULATION OF IMMUNE CELLS | Octagon Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021155277-A1 | MODULATION OF IMMUNE CELLS | OCTAGON THERAPEUTICS, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230123911-A1 | MODULATION OF IMMUNE CELLS | IMPDH2, IMPDH1, CD74 | SMN1; SMN2 4422/4885LMNA 4750/4885NPC1 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.